Literature DB >> 17696418

Nitrated indenoisoquinolines as topoisomerase I inhibitors: a systematic study and optimization.

Andrew Morrell1, Michael Placzek, Seth Parmley, Smitha Antony, Thomas S Dexheimer, Yves Pommier, Mark Cushman.   

Abstract

The biological activity of indenoisoquinoline topoisomerase I (Top1) inhibitors can be greatly enhanced depending on the choice of substituents on the aromatic rings and lactam side chain. Previously, it was discovered that a 3-nitro group and a 9-methoxy group afforded enhanced biological activity. In the present investigation, indenoisoquinoline analogues were systematically prepared using combinations of nitro groups, methoxy groups, and hydrogen atoms in an effort to understand the contribution of each group toward cytotoxicity and Top1 inhibition. Analysis of the biological results suggests that the nitro group is important for Top1 inhibition and the methoxy group improves cytotoxicity. In addition, previously identified structure-activity relationships were utilized to select favorable lactam side chain functionalities for incorporation on the aromatic skeleton of analogues in this study. As a result, this investigation has provided optimal Top1 inhibitors equipotent to camptothecin that demonstrate low nanomolar cytotoxicities toward cancer cells.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17696418     DOI: 10.1021/jm070361q

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  21 in total

1.  Design, synthesis, and evaluation of dibenzo[c,h][1,6]naphthyridines as topoisomerase I inhibitors and potential anticancer agents.

Authors:  Evgeny Kiselev; Thomas S Dexheimer; Yves Pommier; Mark Cushman
Journal:  J Med Chem       Date:  2010-11-23       Impact factor: 7.446

2.  Par-4 binds to topoisomerase 1 and attenuates its DNA relaxation activity.

Authors:  Anindya Goswami; Shirley Qiu; Thomas S Dexheimer; Padhma Ranganathan; Ravshan Burikhanov; Yves Pommier; Vivek M Rangnekar
Journal:  Cancer Res       Date:  2008-08-01       Impact factor: 12.701

3.  Discovery of potent indenoisoquinoline topoisomerase I poisons lacking the 3-nitro toxicophore.

Authors:  Daniel E Beck; Monica Abdelmalak; Wei Lv; P V Narasimha Reddy; Gabrielle S Tender; Elizaveta O'Neill; Keli Agama; Christophe Marchand; Yves Pommier; Mark Cushman
Journal:  J Med Chem       Date:  2015-04-24       Impact factor: 7.446

4.  7-azaindenoisoquinolines as topoisomerase I inhibitors and potential anticancer agents.

Authors:  Evgeny Kiselev; Sean DeGuire; Andrew Morrell; Keli Agama; Thomas S Dexheimer; Yves Pommier; Mark Cushman
Journal:  J Med Chem       Date:  2011-08-08       Impact factor: 7.446

5.  Synthesis and biological evaluation of nitrated 7-, 8-, 9-, and 10-hydroxyindenoisoquinolines as potential dual topoisomerase I (Top1)-tyrosyl-DNA phosphodiesterase I (TDP1) inhibitors.

Authors:  Trung Xuan Nguyen; Monica Abdelmalak; Christophe Marchand; Keli Agama; Yves Pommier; Mark Cushman
Journal:  J Med Chem       Date:  2015-03-26       Impact factor: 7.446

6.  Synthesis and biological evaluation of new fluorinated and chlorinated indenoisoquinoline topoisomerase I poisons.

Authors:  Daniel E Beck; Wei Lv; Monica Abdelmalak; Caroline B Plescia; Keli Agama; Christophe Marchand; Yves Pommier; Mark Cushman
Journal:  Bioorg Med Chem       Date:  2016-02-09       Impact factor: 3.641

7.  Design and Synthesis of Chlorinated and Fluorinated 7-Azaindenoisoquinolines as Potent Cytotoxic Anticancer Agents That Inhibit Topoisomerase I.

Authors:  Mohamed S A Elsayed; Yafan Su; Ping Wang; Taresh Sethi; Keli Agama; Azhar Ravji; Christophe E Redon; Evgeny Kiselev; Katharine A Horzmann; Jennifer L Freeman; Yves Pommier; Mark Cushman
Journal:  J Med Chem       Date:  2017-06-28       Impact factor: 7.446

8.  Synthesis and biological evaluation of indenoisoquinolines that inhibit both tyrosyl-DNA phosphodiesterase I (Tdp1) and topoisomerase I (Top1).

Authors:  Martin Conda-Sheridan; P V Narasimha Reddy; Andrew Morrell; Brooklyn T Cobb; Christophe Marchand; Keli Agama; Adel Chergui; Amélie Renaud; Andrew G Stephen; Lakshman K Bindu; Yves Pommier; Mark Cushman
Journal:  J Med Chem       Date:  2012-12-21       Impact factor: 7.446

9.  The indenoisoquinoline noncamptothecin topoisomerase I inhibitors: update and perspectives.

Authors:  Yves Pommier; Mark Cushman
Journal:  Mol Cancer Ther       Date:  2009-04-21       Impact factor: 6.261

10.  Design, Synthesis, and Biological Evaluation of Potential Prodrugs Related to the Experimental Anticancer Agent Indotecan (LMP400).

Authors:  Peng-Cheng Lv; Mohamed S A Elsayed; Keli Agama; Christophe Marchand; Yves Pommier; Mark Cushman
Journal:  J Med Chem       Date:  2016-04-20       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.